Literature DB >> 10310324

Evaluation of public investment in health care. Is the risk irrelevant?

U Ben-Zion, A Gafni.   

Abstract

In this note we discuss the application of developments in economic theory to the evaluation of 'Risky' public health programs. We show that the use of expected values as measures of outcome in such programs is inappropriate. Instead we suggest the use of certainty equivalent values measured by a direct assessment (the 'Standard Gamble') as an appropriate way to evaluate the outcome.

Mesh:

Year:  1983        PMID: 10310324     DOI: 10.1016/0167-6296(83)90005-x

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  8 in total

Review 1.  Theoretical arguments for the discounting of health consequences: where do we go from here?

Authors:  Angelina Lazaro
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).

Authors:  A Mehrez; A Gafni
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

3.  Ionic versus nonionic contrast media: a burden or a bargain?

Authors:  A Gafni; C J Zylak
Journal:  CMAJ       Date:  1990-09-15       Impact factor: 8.262

4.  Alternatives to the QALY measure for economic evaluations.

Authors:  A Gafni
Journal:  Support Care Cancer       Date:  1997-03       Impact factor: 3.603

5.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.

Authors:  A Gafni; S Birch
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

6.  The standard gamble method: what is being measured and how it is interpreted.

Authors:  A Gafni
Journal:  Health Serv Res       Date:  1994-06       Impact factor: 3.402

7.  Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.

Authors:  Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2022-02-09       Impact factor: 4.558

8.  Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.

Authors:  Pedram Sendi
Journal:  Pharmacoeconomics       Date:  2020-10-31       Impact factor: 4.981

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.